Galectin Therapeutics Inc. (NASDAQ:GALT – Get Rating) Director Richard A. Jr. Zordani bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The stock was purchased at an average cost of $2.50 per share, with a total value of $12,500.00. Following the completion of the purchase, the director now directly owns 29,583 shares of the company’s stock, valued at approximately $73,957.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Galectin Therapeutics Trading Down 8.9 %
Shares of Galectin Therapeutics stock opened at $2.26 on Monday. The business has a fifty day simple moving average of $1.51 and a two-hundred day simple moving average of $1.67. Galectin Therapeutics Inc. has a 1 year low of $1.19 and a 1 year high of $4.24. The company has a market capitalization of $134.22 million, a price-to-earnings ratio of -3.90 and a beta of 1.55. The company has a debt-to-equity ratio of 79.37, a current ratio of 3.51 and a quick ratio of 3.51.
Galectin Therapeutics (NASDAQ:GALT – Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Research analysts forecast that Galectin Therapeutics Inc. will post -0.75 EPS for the current year.
Institutional Investors Weigh In On Galectin Therapeutics
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. HC Wainwright decreased their target price on shares of Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. StockNews.com began coverage on shares of Galectin Therapeutics in a research note on Thursday. They issued a “sell” rating for the company.
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.